Trials / Withdrawn
WithdrawnNCT04151563
A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy
A Phase 1/2, Randomized Study Evaluating Multiple Nivolumab Combination Therapies in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy and Anti-PD-1 (L)1 Immunotherapy
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is for participants with Non-small Cell Lung Cancer that has spread or has reoccurred after failure of Chemotherapy and Immunotherapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | nivolumab | Specified dose on Specified days |
| BIOLOGICAL | ipilimumab | Specified dose on Specified days |
| DRUG | cabozantinib | Specified dose on Specified days |
| BIOLOGICAL | docetaxel | Specified dose on Specified days |
| BIOLOGICAL | ramucirumab | Specified dose on Specified days |
| DRUG | lucitanib | Specified dose on Specified days |
Timeline
- Start date
- 2021-04-15
- Primary completion
- 2023-12-17
- Completion
- 2026-05-13
- First posted
- 2019-11-05
- Last updated
- 2023-12-19
Locations
23 sites across 10 countries: United States, Argentina, Belgium, Denmark, Greece, Mexico, Netherlands, Norway, Poland, Romania
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04151563. Inclusion in this directory is not an endorsement.